Unity Biotechnology Investor Relations Material

Unity Biotechnology, Inc., a biotechnology company, focuses on developing therapeutics designed to slow, halt, or reverse diseases associated with aging. The company's research primarily targets cellular senescence and age-related biology, with an emphasis on ophthalmologic and neurologic diseases. Unity Biotechnology's product pipeline includes UBX1325, currently in clinical trials for treating age-related eye diseases such as diabetic macular edema and age-related macular degeneration. It is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.